Your browser doesn't support javascript.
Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests.
Yamaoka, Yutaro; Miyakawa, Kei; Jeremiah, Sundararaj Stanleyraj; Funabashi, Rikako; Okudela, Koji; Kikuchi, Sayaka; Katada, Junichi; Wada, Atsuhiko; Takei, Toshiki; Nishi, Mayuko; Shimizu, Kohei; Ozawa, Hiroki; Usuku, Shuzo; Kawakami, Chiharu; Tanaka, Nobuko; Morita, Takeshi; Hayashi, Hiroyuki; Mitsui, Hideaki; Suzuki, Keita; Aizawa, Daisuke; Yoshimura, Yukihiro; Miyazaki, Tomoyuki; Yamazaki, Etsuko; Suzuki, Tadaki; Kimura, Hirokazu; Shimizu, Hideaki; Okabe, Nobuhiko; Hasegawa, Hideki; Ryo, Akihide.
  • Yamaoka Y; Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan.
  • Miyakawa K; Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., Isehara, Kanagawa 259-1146, Japan.
  • Jeremiah SS; Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan.
  • Funabashi R; Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan.
  • Okudela K; Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan.
  • Kikuchi S; Department of Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan.
  • Katada J; Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., Isehara, Kanagawa 259-1146, Japan.
  • Wada A; Medical Systems Research & Development Center, FUJIFILM Corporation, Kaisei, Kanagawa 258-8538, Japan.
  • Takei T; Medical Systems Research & Development Center, FUJIFILM Corporation, Kaisei, Kanagawa 258-8538, Japan.
  • Nishi M; Medical Systems Research & Development Center, FUJIFILM Corporation, Kaisei, Kanagawa 258-8538, Japan.
  • Shimizu K; Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan.
  • Ozawa H; Yokohama City Institute of Public Health, Yokohama, Kanagawa 236-0051, Japan.
  • Usuku S; Yokohama City Institute of Public Health, Yokohama, Kanagawa 236-0051, Japan.
  • Kawakami C; Yokohama City Institute of Public Health, Yokohama, Kanagawa 236-0051, Japan.
  • Tanaka N; Yokohama City Institute of Public Health, Yokohama, Kanagawa 236-0051, Japan.
  • Morita T; Yokohama City Institute of Public Health, Yokohama, Kanagawa 236-0051, Japan.
  • Hayashi H; Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan.
  • Mitsui H; Division of Pathology, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa 221-0855, Japan.
  • Suzuki K; Department of Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan.
  • Aizawa D; Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., Isehara, Kanagawa 259-1146, Japan.
  • Yoshimura Y; Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., Isehara, Kanagawa 259-1146, Japan.
  • Miyazaki T; Division of Infectious Disease, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa 221-0855, Japan.
  • Yamazaki E; Department of Physiology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan.
  • Suzuki T; Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Kanagawa 236-0004, Japan.
  • Kimura H; Department of Pathology, National Institute of Infectious Diseases, Shinjuku, Tokyo 162-8640, Japan.
  • Shimizu H; School of Medical Technology, Faculty of Health Sciences, Gunma Paz University, Takasaki, Gunma 370-0006, Japan.
  • Okabe N; Division of Virology, Kawasaki City Institute for Public Health, Kawasaki, Kanagawa 210-0821, Japan.
  • Hasegawa H; Division of Virology, Kawasaki City Institute for Public Health, Kawasaki, Kanagawa 210-0821, Japan.
  • Ryo A; Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama, Tokyo 208-0011, Japan.
Cell Rep Med ; 2(6): 100311, 2021 Jun 15.
Article in English | MEDLINE | ID: covidwho-1230816
Semantic information from SemMedBD (by NLM)
1. Measles Virus Nucleoprotein PART_OF 2019 novel coronavirus
Subject
Measles Virus Nucleoprotein
Predicate
PART_OF
Object
2019 novel coronavirus
2. Antigen test USES Detection
Subject
Antigen test
Predicate
USES
Object
Detection
3. Antigen test USES Measles Virus Nucleoprotein
Subject
Antigen test
Predicate
USES
Object
Measles Virus Nucleoprotein
4. Monoclonal Antibodies INTERACTS_WITH Epitopes
Subject
Monoclonal Antibodies
Predicate
INTERACTS_WITH
Object
Epitopes
5. Enzyme-Linked Immunosorbent Assay USES Monoclonal Antibodies
Subject
Enzyme-Linked Immunosorbent Assay
Predicate
USES
Object
Monoclonal Antibodies
6. Measles Virus Nucleoprotein PART_OF 2019 novel coronavirus
Subject
Measles Virus Nucleoprotein
Predicate
PART_OF
Object
2019 novel coronavirus
7. Antigen test USES Detection
Subject
Antigen test
Predicate
USES
Object
Detection
8. Antigen test USES Measles Virus Nucleoprotein
Subject
Antigen test
Predicate
USES
Object
Measles Virus Nucleoprotein
9. Monoclonal Antibodies INTERACTS_WITH Epitopes
Subject
Monoclonal Antibodies
Predicate
INTERACTS_WITH
Object
Epitopes
10. Enzyme-Linked Immunosorbent Assay USES Monoclonal Antibodies
Subject
Enzyme-Linked Immunosorbent Assay
Predicate
USES
Object
Monoclonal Antibodies
ABSTRACT
The ongoing coronavirus disease 2019 (COVID-19) pandemic is a major global public health concern. Although rapid point-of-care testing for detecting viral antigen is important for management of the outbreak, the current antigen tests are less sensitive than nucleic acid testing. In our current study, we produce monoclonal antibodies (mAbs) that exclusively react with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and exhibit no cross-reactivity with other human coronaviruses, including SARS-CoV. Molecular modeling suggests that the mAbs bind to epitopes present on the exterior surface of the nucleocapsid, making them suitable for detecting SARS-CoV-2 in clinical samples. We further select the optimal pair of anti-SARS-CoV-2 nucleocapsid protein (NP) mAbs using ELISA and then use this mAb pair to develop immunochromatographic assay augmented with silver amplification technology. Our mAbs recognize the variants of concern (501Y.V1-V3) that are currently in circulation. Because of their high performance, the mAbs of this study can serve as good candidates for developing antigen detection kits for COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Type of study: Diagnostic study Language: English Journal: Cell Rep Med Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Type of study: Diagnostic study Language: English Journal: Cell Rep Med Year: 2021
...